ArticleDiscover oncology2026
Mendelian randomization analysis of inflammatory proteins and lung adenocarcinoma risk.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the potential causal effects of six circulating inflammatory proteins on lung adenocarcinoma risk using Mendelian randomization.
methodsGenetic instrumental variables were selected from genome-wide association study (GWAS) summary statistics for six inflammatory proteins (beta-nerve growth factor, C-C motif chemokine 25, cystatin D, interleukin-18, tumor necrosis factor, and VEGF-A). Three Mendelian randomization methods, including inverse-variance weighted (IVW) analysis as the primary method, MR-Egger regression, and weighted median analysis, were applied with a relaxed instrument selection threshold of P < 1 × 10^-5. Sensitivity analyses were conducted to assess heterogeneity, horizontal pleiotropy, and the stability of the findings.
resultsAmong the six inflammatory proteins examined, C-C motif chemokine 25 (CCL25) showed a significant causal association with increased lung adenocarcinoma risk (IVW OR = 1.055, 95% CI: 1.021-1.090, P = 0.0013), which survived Bonferroni correction for multiple testing (threshold P < 0.0083). Beta-nerve growth factor, cystatin D, interleukin-18, tumor necrosis factor, and VEGF-A did not show significant associations after correction. Sensitivity analyses did not indicate substantial horizontal pleiotropy, though interleukin-18 showed evidence of heterogeneity (Cochran Q P = 0.002).
conclusionsAmong six circulating inflammatory proteins, C-C motif chemokine 25 was significantly associated with increased lung adenocarcinoma risk, whereas the remaining five proteins showed null associations after correction for multiple testing. These findings suggest a specific rather than generalized role of inflammatory mediators in lung adenocarcinoma risk. Results should be interpreted cautiously because of the relaxed instrument selection threshold and the need for external validation in independent populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.